Open Access
Issue
Regen Med Res
Volume 7, 2019
Article Number 2
Number of page(s) 9
DOI https://doi.org/10.1051/rmr/190002
Published online 10 December 2019
  1. Ahmad RS, Barritault D (2018), ReGeneraTing Agents (RGTA(R)) are a new option to improve amputation outcomes in the recovery of severe hand injuries, Clin Case Rep 6, 2061–2069. [PubMed] [Google Scholar]
  2. Albert S (2002), Cost-effective management of recalcitrant diabetic foot ulcers. Clin Podiatr Med Surg 19, 483–491. [Google Scholar]
  3. ATIH 2017; Available from: https://www.scansante.fr/applications/cout-finance. [Google Scholar]
  4. Barbier-Chassefiere V, Garcia‐Filipe S, Yue XL, Kerros ME, Petit E, Kern P, Saffar JL, Papy‐Garcia D, Caruelle JP, Barritault D (2009), Matrix therapy in regenerative medicine, a new approach to chronic wound healing, J Biomed Mater Res A 90, 641–647. [CrossRef] [PubMed] [Google Scholar]
  5. Bircher AJ, Fluckiger R, Buchner SA (1990), Eczematous infiltrated plaques to subcutaneous heparin: a type IV allergic reaction. Br J Dermatol 123, 507–514. [CrossRef] [PubMed] [Google Scholar]
  6. Chebbi CK, Kichenin K, Amar N, Nourry H, Warnet JM, Barritault D, Baudouin C (2008), Pilot study of a new matrix therapy agent (RGTA OTR4120) in treatment-resistant corneal ulcers and corneal dystrophy. J Fr Ophtalmol 31, 465–471. [CrossRef] [PubMed] [Google Scholar]
  7. Desgranges P, Barbaud C, Caruelle JP, Barritault D, Gautron J (1999), A substituted dextran enhances muscle fiber survival and regeneration in ischemic and denervated rat EDL muscle. FASEB J 13, 761–766. [CrossRef] [PubMed] [Google Scholar]
  8. Dillingham TR, Pezzin LE, Shore AD (2005), Reamputation, mortality, and health care costs among persons with dysvascular lower-limb amputations. Arch Phys Med Rehabil 86, 480–486. [CrossRef] [PubMed] [Google Scholar]
  9. Franklin H, Rajan M, Tseng CL, Pogach L, Sinha A, Mph M (2014), Cost of lower-limb amputation in U.S. veterans with diabetes using health services data in fiscal years 2004 and 2010. J Rehabil Res Dev 51, 1325–1330. [CrossRef] [PubMed] [Google Scholar]
  10. Gupta U, Verma M (2013), Placebo in clinical trials. Perspect Clin Res 4, 49–52. [Google Scholar]
  11. Langer A, Rogowski W (2009), Systematic review of economic evaluations of human cell-derived wound care products for the treatment of venous leg and diabetic foot ulcers. BMC Health Serv Res 9, 115. [CrossRef] [PubMed] [Google Scholar]
  12. Roohi SA, Barritault D (2019), ReGeneraTing Agents (RGTA(R)): A new option for healing and improving treatment outcomes for traumatic and burn injuries of the hand. Clin Case Rep 7, 619–625. [PubMed] [Google Scholar]
  13. salariés, C.N.d.l.a.m.d.t., Améliorer la qualité du système de santé et maîtriser les dépenses: propositions de l'Assurance Maladie pour 2014. 2014: France. p. 80–85. [Google Scholar]
  14. Saliba MJ Jr (2001), Heparin in the treatment of burns: a review 27, 349–358. [Google Scholar]
  15. Singer AJ, Tassiopoulos A, Kirsner RS (2017), Evaluation and management of lower-extremity ulcers. N Engl J Med 377, 1559–1567. [Google Scholar]
  16. Tong M, Tuk B, Hekking IM, Pleumeekers MM, Boldewijn MB, Hovius SE, van Neck JW (2011), Heparan sulfate glycosaminoglycan mimetic improves pressure ulcer healing in a rat model of cutaneous ischemia-reperfusion injury, Wound Repair Regen 19, 505–514. [CrossRef] [PubMed] [Google Scholar]
  17. World Medical (2013), World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA 310, 2191–2194. [CrossRef] [PubMed] [Google Scholar]
  18. Yamauchi H, Desgranges P, Lecerf L, Papy D, Tournaire MC, Moczar M, Loisance D, Barritault D (2000), New agents for the treatment of infarcted myocardium. FASEB J 14, 2133–2134. [CrossRef] [PubMed] [Google Scholar]
  19. Zelen CM, Serena TE, Gould L, Le L, Carter MJ, Keller J, Li WW (2016), Treatment of chronic diabetic lower extremity ulcers with advanced therapies: a prospective, randomised, controlled, multi-centre comparative study examining clinical efficacy and cost. Int Wound J 13, 272–282. [CrossRef] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.